Original reporting and analysis on the stories shaping biotech.
Eli Lilly is pushing a gene-editing therapy into Phase 2 that could permanently slash cholesterol with a single infusion. It's the biggest bet yet that CRISPR-era medicine can tackle the world's leading killer, not just rare diseases.
Gilead just agreed to pay up to $2.2 billion for Ouro Medicines, a startup that's barely a year old. The deal centers on an "immune reset" drug that could reshape how we treat autoimmune diseases, and Gilead isn't even paying the full tab.
Eli Lilly is paying up to $7 billion for a tiny biotech that wants to reprogram your immune cells without ever taking them out of your body. It's the boldest bet yet in the race to make CAR-T therapy as simple as an IV drip.
A Paragon Therapeutics spinout just raised $290 million to chase a migraine target that isn't CGRP, going public through a reverse merger before testing its drugs in a single human. The investor roster is stacked, but the science is still unproven.
The FDA's new "plausible mechanism" framework could let gene therapies for ultra-rare diseases reach patients without massive clinical trials. It's the biggest regulatory shift in years, and it might finally fix the impossible economics that have kept cures on the shelf.
Eli Lilly dropped $202 million on a startup with zero human data and a technology that could make viral gene therapy delivery obsolete. The bet makes more sense than you'd think.
Regeneron and Telix Pharmaceuticals just struck a deal worth up to $4.3 billion to co-develop radioligand cancer therapies. It's one of the largest radiopharma alliances ever, and it confirms that every major oncology player now wants nuclear-powered cancer drugs in their arsenal.
FDA staff are raising alarms about who actually has the authority to approve drugs under the Priority Review Voucher system. With vouchers now selling for up to $200 million and billions in rare disease investment hanging in the balance, the confusion couldn't come at a worse time.
Novartis spent years perfecting T-Charge, a platform that compresses CAR-T manufacturing from weeks to under two days. But five major pharma companies just spent billions buying technology that could skip the factory entirely. The race between faster manufacturing and no manufacturing at all is the biggest bet in cell therapy.
Europe's drug regulator just recommended both an oral version of Wegovy and a preemptive breast cancer therapy in one session. One could bring needle-free GLP-1 treatment to millions; the other catches tumor resistance before it strikes.
The FDA just approved the first BCL-2 inhibitor specifically for mantle cell lymphoma, giving patients who've failed multiple treatments a new oral option. Sonrotoclax promises higher potency and fewer headaches than its predecessor venetoclax, but the real test is still ahead.
The FDA just approved the first new mechanism for lowering blood pressure in over a decade. Baxfendy shuts off your body's "salt thermostat" instead of just blocking it, and it could reshape treatment for millions of patients whose numbers won't budge.
The FDA has lost roughly 3,500 employees in six months, and biotech companies are racing to scoop up the regulatory talent walking out the door. Former FDA leader Stephen Hahn's jump to Turn Therapeutics is just the latest sign of a brain drain reshaping both the agency and the industry.
AbbVie and Novartis both filed U.S. layoff notices in the same week, continuing a restructuring wave sweeping big pharma. The cuts aren't signs of weakness; they're signs of a much bigger transformation underway.
A Paragon Biosciences spinout just raised $290 million to go after migraine prevention with a totally different approach. The bet: current drugs leave half of patients undertreated, and a protein called PACAP could be the missing piece.
A small French biotech just did what Big Pharma couldn't: get an immunotherapy to work in ovarian cancer. OSE Immunotherapeutics' cancer vaccine Tedopi cut progression risk by 47% in a Phase 2 trial, cracking open one of oncology's most stubborn indications.
The FDA decides on May 29 whether kids as young as four can trade mealtime insulin needles for an inhaler. If approved, Afrezza would be the first needle-free insulin ever cleared for children, and the clinical data is raising eyebrows for all the right (and a few tricky) reasons.
The FDA just delayed its decision on a subcutaneous version of Leqembi that could let Alzheimer's patients skip 39 IV infusions entirely. The three-month pushback to August 2026 matters more than it sounds, because the biggest barrier to Leqembi's success isn't the science; it's getting patients to show up.
A Chinese-made antibody-drug conjugate just supercharged Keytruda in a landmark lung cancer trial, cutting the risk of progression by 65%. It's the first ADC-immunotherapy combo to win in frontline lung cancer, and it could reshape Merck's entire post-patent strategy.
Eli Lilly's retatrutide, a triple gut-hormone agonist, just posted Phase 3 weight loss numbers that rival bariatric surgery: nearly 29% body weight gone in 80 weeks. The obesity drug race just got a new frontrunner, and the competition is scrambling.
Prediction markets are letting people bet real money on clinical trial outcomes and FDA decisions. The potential for cleaner investing signals is real, but so are the insider trading risks and ethical landmines that come with gambling on whether a drug will save lives.
A tiny, pre-clinical biotech just agreed to buy an AI-driven CAR-T startup for $320 million in stock. The science is fascinating, but the deal structure is raising eyebrows across the industry.
Join thousands of biotech professionals who start their day with our free, daily briefing.